The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Rational design of inhibitors that bind to inactive kinase conformations
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Crystal structure of the tyrosine kinase domain of the human insulin receptor
Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Self-citationStructural basis of inhibitor selectivity in MAP kinases
Wang, Z., Canagarajah, B. J., Boehm, J. C., Kassisà, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, J. L., & Goldsmith, E. J. (1998) · Structure · doi:10.1016/s0969-2126(98)00113-0 · Cited by 423
Cited by
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Self-citationComprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Molecular Recognition in Chemical and Biological Systems
Persch, E., Dumele, O., & Diederich, F. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201408487 · Cited by 654
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Self-citationRegulation of RIP1 kinase signalling at the crossroads of inflammation and cell death
Ofengeim, D., & Yuan, J. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3683 · Cited by 621
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901443h · Cited by 518
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
“Such inhibitors prevent kinase activation and usually possess potent cellular activity because they recognize and promote kinase conformations that have low affinity for AT”
BackgroundTargeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 440
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Self-citationErlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Park, J. H., Liu, Y., Lemmon, M. A., & Radhakrishnan, R. (2012) · Biochemical Journal · doi:10.1042/bj20121513 · Cited by 426
Self-citationNew approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
Atropisomerism in Medicinal Chemistry: Challenges and Opportunities
Toenjes, S. T., & Gustafson, J. L. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0152 · Cited by 382
Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential
Feng, Y., LoGrasso, P. V., Defert, O., & Li, R. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00683 · Cited by 378
Critical roles of non-histone protein lysine methylation in human tumorigenesis
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376
Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
Munoz, L., & Ammit, A. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.010 · Cited by 369
Rational Approaches to Improving Selectivity in Drug Design
Huggins, D. J., Sherman, W., & Tidor, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010332 · Cited by 367
Deacon, S. W., Beeser, A., Fukui, J. A., Rennefahrt, U. E. E., Myers, C., Chernoff, J., & Peterson, J. R. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.03.005 · Cited by 366
Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum
Solyakov, L., Halbert, J., Alam, M. M., Semblat, J.-P., Dorin-Semblat, D., Reininger, L., Bottrill, A. R., Mistry, S., Abdi, A., Fennell, C., et al. (2011) · Nature Communications · doi:10.1038/ncomms1558 · Cited by 362
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Müller, S., Bullock, A. N., Schwaller, J., Sundström, M., & Knapp, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708800104 · Cited by 359
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 349
Self-citationIn Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E., Herring, C., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.011 · Cited by 348
Self-citationTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery
Pryde, D. C., Dalvie, D., Hu, Q., Jones, P., Obach, R. S., & Tran, T.-D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100888d · Cited by 345
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A. D., Darrow, J., Davies, D. R., DeForge, L. E., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.481 · Cited by 340
Dual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Modi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 320
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
Flying under the radar: the new wave of BCR–ABL inhibitors
Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2324 · Cited by 305
Probing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 299
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 298
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Cowan-Jacob, S. W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., Rheinberger, P., Centeleghe, M., Fabbro, D., & Manley, P. W. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906047287 · Cited by 296
The (un)targeted cancer kinome
Fedorov, O., Müller, S., & Knapp, S. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.297 · Cited by 292
The regulation of protein phosphorylation
Johnson, L. N. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370627 · Cited by 291
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Dai, S., Zhou, Z., Chen, Z., Xu, G., & Chen, Y. (2019) · Cells · doi:10.3390/cells8060614 · Cited by 288
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500394m · Cited by 285
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase
Garcin, E. D., Arvai, A. S., Rosenfeld, R. J., Kroeger, M. D., Crane, B. R., Andersson, G., Andrews, G., Hamley, P. J., Mallinder, P. R., Nicholls, D. J., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.115 · Cited by 274
A conserved protonation-dependent switch controls drug binding in the Abl kinase
Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. Ø., Dror, R. O., Kuriyan, J., & Shaw, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811223106 · Cited by 262
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Sato, T., Yang, X., Knapper, S., White, P., Smith, B. D., Galkin, S., Small, D., Burnett, A., & Levis, M. (2011) · Blood · doi:10.1182/blood-2010-01-266742 · Cited by 261
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
ROCK inhibition in models of neurodegeneration and its potential for clinical translation
Koch, J. C., Tatenhorst, L., Roser, A.-E., Saal, K.-A., Tönges, L., & Lingor, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.008 · Cited by 239
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Molecular Insight of Regorafenib Treatment for Colorectal Cancer
Arai, H., Battaglin, F., Wang, J., Lo, J. H., Soni, S., Zhang, W., & Lenz, H.-J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101912 · Cited by 191
Principles of inflammasome priming and inhibition: implications for psychiatric disorders
Herman, F. J., & Pasinetti, G. M. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.010 · Cited by 115
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Rational Engineering of Enzyme Allosteric Regulation through Sequence Evolution Analysis
Yang, J.-S., Seo, S. W., Jang, S., Jung, G. Y., & Kim, S. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002612 · Cited by 87
Roser, A.-E., Tönges, L., & Lingor, P. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00094 · Cited by 77
The Basis for Target‐Based Virtual Screening: Protein Structures
Cole, J. C., Korb, O., Olsson, T. S. G., & Liebeschuetz, J. (2011) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633326.ch4 · Cited by 9
Metadata
- Authors
- Liu, Y., & Gray, N. S.
- Venue
- Nature Chemical Biology
- Published
- 2006-06-16
- Volume
- 2
- Issue
- 7
- Pages
- 358-364
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2079398727
- Cited by
- 1,094
- References
- 28
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.